Bluejay Diagnostics (BJDX) FCF Margin (2022)
Bluejay Diagnostics (BJDX) posted FCF Margin of 734.6% for Q2 2022.
Bluejay Diagnostics (BJDX) FCF Margin (2022) Analysis & Trends
Bluejay Diagnostics has reported FCF Margin for 1 years, with the latest figure at 734.6% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 15.81% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 16.07% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 23.50% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 33.60% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 14.10% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 1.28% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 5.32% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 18.73% |
| 10 | Bluejay Diagnostics | 1.91 Mn | 1.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -734.60% |